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Abstract 
 
Purpose 
To assess feasibility and reproducibility of an Active Breathing Co-ordinator used 
throughout radical radiotherapy for non-small cell lung cancer, and compare lung 
dosimetric parameters between free-breathing and ABC plans. 
 
Methods and Materials 
18 patients, recruited into an approved study, had free-breathing and ABC 
breath-hold treatment plans generated. Lung volume, V20 and MLD were 
compared. Treatment (64 Gy in 32 fractions, 5 days/week) was delivered in 
breath-hold. Repeat breath-hold CT scans were used to assess change in GTV 
size and position. Set-up error was also measured and potential GTV-PTV 
margins calculated. 
 
Results 
17/18 patients completed RT using ABC daily. Intrafraction tumour position was 
consistent but interfraction variation had mean (standard deviation) values of 4.5 
(5.2), 3.5 (2.9) and 3.4 (3.8) mm in the superior-inferior (SI), right-left (RL) and 
antero-posterior (AP) directions respectively. Tumour moved partially outside the 
PTV in 5 patients. Mean reduction in GTV volume from planning to end of 
treatment was 25 % (p = 0.003). Potentially required PTV margins were 17.5, 
11.5 and 11.4 mm in SI, RL and AP directions. ABC reduced V20 by 13 % (p = 
  Brock 3 
0.0001), V13 by 12 % (p = 0.001) and MLD by 13 % (p < 0.001) compared to free-
breathing; lung volume increased by 41 % (p < 0.001). 
 
Conclusions 
Clinically significant movements of GTV were seen during RT for NSCLC using 
ABC.  Image guidance and adaptive RT are recommended with ABC.  However 
even without margin reduction ABC reduces the risk of lung toxicity and should 
allow dose escalation.  
 
Keywords: lung; radiotherapy; ABC; interfraction variation; margins 
 
  Brock 4 
Introduction 
External beam radiotherapy (RT), with or without chemotherapy, is the treatment 
of choice for inoperable non-small cell lung cancer (NSCLC), although with 
standard techniques local disease control and survival are disappointing. There 
is evidence for a dose-response effect [1, 2] and for improved outcome with 
increased dose intensity [3]. However, dose escalation is limited by normal tissue 
toxicity, particularly of the lung. Attempts to increase dose above lung tolerance 
have been associated with increased radiation-induced pneumonitis [4, 5], while 
concomitant chemotherapy is associated with increased oesophagitis [6-11]. 
 
In current practice the size of the RT planning target volume (PTV) takes into 
account the movement of the tumour with respiration and consequent uncertainty 
of the tumour position, as well as uncertainties about patient position and other 
errors [12]. As a result a significant volume of normal lung tissue is included in 
the PTV.  
 
The aim of modern RT is to reduce the dose and /or volume of normal tissue 
treated, particularly the lung, to allow for safe dose escalation to the tumour. One 
of the options is to control for tumour motion with respiration, and two main 
strategies to achieve this exist. Tumour motion can be unrestricted and 
monitored, with delivery of RT gated to a pre-defined phase of the respiratory 
cycle [13-15] or following the moving tumour [16]. Alternatively motion can be 
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minimized by planning and treating in passive [17-21]  or active [22, 23] breath-
hold. 
 
We previously assessed the potential benefit of an active breath-hold technique 
using the Active Breathing Co-ordinator (Elekta Oncology systems Ltd Crawley, 
West Sussex, UK). Patients receiving radical radiotherapy were scanned in 
moderate deep inspiration breath-hold using ABC prior to, in the middle and in 
the final week of the treatment course. The use of ABC during the computed 
tomography (CT) scans was tolerated by 25 out of 30 (83%) patients. The 
random contribution of periodic tumour motion was reduced by 90% in the 
superior-inferior direction compared with free-breathing, and the reduction in PTV 
size with ABC resulted in an 18-25% relative reduction in physical lung 
parameters [24]. 
 
In this study the ABC device was used throughout a 6 week course of radical 
radiotherapy for NSCLC. We assessed feasibility and the effect on tumour 
position reproducibility between consecutive breath-holds and over the treatment 
course. We also assessed the potential benefit of ABC on lung dosimetric 
parameters and margins. 
 
Patients and methods 
The study protocol was approved by the local Committee for Clinical  
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Research (CCR) and Local Research Ethics Committee (REC). Eligible patients, 
due to receive radical RT for NSCLC, were consented in accordance with 
international and local guidelines.  
 
Between April 2006 and August 2008 18 patients were entered in the study. All 
fulfilled the eligibility criteria of unresectable or inoperable locally advanced 
NSCLC, stage I – IIIB, WHO performance status 0 – 1, ability to give written 
informed consent and to comprehend instructions about the ABC procedure, and 
an ability to maintain breath-hold for at least 15 seconds with ABC. 
 
The mean age of 18 assessable patients was 68 years (range 44 – 85) and the 
majority had stage IIIA or IIIB disease (Table 1).  
 
Equipment 
The use of the ABC device in our institution has been described previously [24]. 
Radiotherapy planning CT scans were acquired (Philips Brilliance CT Big Bore, 
Philips Medical Systems, UK) according to a standard protocol (2 mm slice 
thickness, collimation 16 x 1.5 mm, pitch 0.813, field of view 600 mm, rotation 
time 0.75 seconds, table speed 26 mm/second). Intravenous contrast was used 
in patients with adequate renal function. Images were transferred to the 
Pinnacle3 treatment planning system (Philips, Reigate, UK).  
 
Image acquisition 
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With the patient in the treatment position, and following training with the ABC 
device, a free-breathing CT was performed with the patient instructed to breathe 
normally. The ABC mouthpiece and nose-clip were then attached and 3 CT 
scans with breath hold at approximately 70% of maximum inspiratory volume 
were acquired (ABCbase1, ABCbase2 and ABCbase3) in the same position. 
Tattoos to aid patient set-up were marked in free breathing. 
 
Further CT scans in the treatment position and in breath-hold were performed in 
the middle (ABCmid) and at the end (ABCend) of the treatment course. 
 
Target localization 
Target localization was standardized with a set of guidelines aimed at minimizing 
intraobserver and interobserver variation. These included pre-set CT 
window/levels for use in contouring each region of interest, and specific 
instructions for fusing images. 
 
On the free-breathing (FB) scan, visible tumour and involved lymph nodes (≥ 1 
cm in diameter on CT and PET positive) were outlined and defined as the ‘free-
breathing gross tumour volume’ (FBGTV). Spinal cord, normal lung (defined as 
both lungs as a single organ minus the GTV), heart and oesophagus were also 
outlined. The ‘free-breathing planning target volume’ (FBPTV) was generated by 
expanding the GTV by 1.5 cm in the superior-inferior direction and 1.0 cm axially. 
The co-ordinates for the FBGTV target centre (generated by the treatment 
  Brock 8 
planning system using a spherical autoplace function as the “centre of mass”, 
COM) and the volume of FBGTV, FBPTV and both lungs were recorded. 
 
The same structures were outlined on the ABCbase1 scan (fused with the free-
breathing images aligned using bony anatomy close to the tumour). ABC1PTV 
was generated using an identical margin (as above). The co-ordinates for the 
ABC1GTV centre of mass and the volumes of ABC1GTV, ABC1PTV and both 
lungs were recorded. 
 
Similarly GTV and both lungs were outlined on ABC base2, ABCbase3, ABCmid 
and ABCend CT scans. 
 
Planning 
Conventional multiple field conformal RT was planned on the first ABC breath-
hold scan (ABCbase1) using the Pinnacle3 treatment planning system and 
incorporating tissue inhomogeneity correction. A back-up treatment plan using 
the same beam arrangement was also prepared for the free-breathing scan in 
case of poor ABC tolerance and for comparison of dose volume parameters. 
After clinical acceptance of both plans the isocentre was verified using 
fluoroscopy.  
 
Treatment  
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Treatment was delivered using multiple ABC breath-holds, given in 32 fractions 
of 2 Gy over 61/2 weeks (total 64Gy). Electronic portal imaging (EPI) was used to 
verify the patient set-up position. 
 
Data acquisition 
Assessment of intrafraction tumour position 
Contours from ABCbase1 and ABCbase2 were imported into the ABCbase3 
image dataset. Images were aligned using the bony anatomy of the spine in the 
region of the tumour, viewed in 3 planes. This was initially performed manually 
and subsequently using an automated function. The COM of the three ABCGTV 
contours were generated and their co-ordinates recorded. The standard deviation 
of displacement of COM of ABC2 and ABC3 relative to ABC1 provided a 
measure of the intrafraction variations of movement of the GTV. Non-overlapping 
volumes for ABC1GTV, ABC2GTV and ABC3GTV were also calculated. 
 
Assessment of interfraction tumour position 
ABCbase1, ABCmid and ABCend images were fused using bony anatomy as 
above. The standard deviation (SD) of the individual mean displacements of the 
COM of ABCmid and ABCend relative to ABC1 provided a measure of the 
systematic interfraction movement of the GTV of the patient group. The group 
random error was determined by calculating the mean of the individual SDs. The 
non-overlap regions comparing ABCmidGTV with ABC1GTV, and ABCendGTV 
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with ABC1GTV were calculated, as was any extent of the contours outside of the 
ABC1PTV. 
 
For the purposes of this study CTV was equivalent to GTV. Potential intra-
observer variation in tumour delineation was not taken into account. 
 
We wished to test whether there was a relationship between change in the size 
of the lesion over the treatment course and shift in the GTV centre. GTV volumes 
in cm3  were recorded from the ABC1 and ABCend CT scans and percentage 
changes calculated. A paired t-test was used to determine the significance of the 
change in GTV volume. 
 
CTV-PTV margin calculation 
A potential CTV-PTV margin using ABC was calculated. Errors were combined in 
quadrature, margin = 2.5∑ + 0.7 σ, where ∑ is total systematic errors and σ total 
random errors of the CTV [25].  
 
Assessment of target and organ at risk dose-volume data 
The percentage volume of lung treated to a dose of ≥ 20 Gy (V20), mean lung 
dose (MLD), the percentage volume of the PTV receiving 90% of the prescription 
dose (PTV90), PTV95 and maximum spinal cord dose were recorded. Mean 
change in each parameter from the free-breathing to the ABC plans was 
calculated.  
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Results 
17/18 patients completed the course of radiotherapy with ABC. One patient 
chose to transfer to treatment with free-breathing after 2 weeks of treatment 
although continued with subsequent ABC breath-hold CT scans and was 
included in the dosimetric analysis.  
 
Assessment of intrafraction tumour position 
Mean intrafraction variation in the GTV COM was 1.7 - 2.0 mm (SD 1.6 - 1.7 mm) 
in the 3 directions (Table 2). As the interim analysis after 12 patients showed 
reproducible intrafraction tumour position with ABC no further measurements 
were carried out. 
 
Assessment of interfraction tumour position 
Significant interfraction tumour position variation (≥ 10 mm) was seen in 5/18 
patients. All movements occurred in either the superior inferior (SI) or anterior 
posterior (AP) directions which consequently had the largest systematic errors 
(Table 3).  The largest recorded shift was 25 mm in the SI direction between 
ABCbase1 and ABCend for patient 1 (Figure 1).The absolute mean interfraction 
variation in breath-hold tumour position ranged from 3.4 to 4.5 mm (Table 2).  
 
For the five patients there was partial movement of the GTV outside of the PTV 
with a mean (range) of 7 % (0.1 - 13 %) of the total GTV volume. This 
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unexpected result led to a modification of the study protocol after 12 patients had 
been treated, with ABC breath-hold CT scans performed at 1-2 weekly intervals 
throughout the course to allow for adaptation of the PTV if required. An 
adjustment of the PTV of > 5mm was required in 1 of the subsequent 6 patients. 
 
There was a mean reduction in GTV volume from ABC1 to ABCend of 25 % (p = 
0.003). For the 5 patients who showed interfraction tumour position variation, 
reduction in GTV volume was calculated as 59, 38, 2, 33 and 24 %. 
  
CTV-PTV margin 
Calculated margins were 17.5 mm, 11.5 mm and 11.4 mm in SI, RL and AP 
directions when using systematic and random set-up (Table 4) and tumour 
position errors (Table 3) using ABC. 
 
If we assume that image guidance and adaptive radiotherapy would at least 
compensate for changes >1cm then remaining ∑ and σ errors of tumour motion 
are 2.5 (2.1), 2.9 (2.5) and 2.7 (2.5) in the SI, RL and AP directions respectively. 
This would give possible CTV - PTV margins of 11.4, 11.6 and 9.9 mm in the SI, 
RL and AP directions.  
 
Assessment of target and organ at risk dose-volume data 
Mean reduction in V20 in 18 patients for ABC plans when compared to free-
breathing plans was 13% (p = 0.0001), reduction in V13 12 % (p = 0.001) and in 
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MLD 13% (p < 0.001). Mean increase in total lung volume with ABC was 41% (p 
< 0.001). 
 
FB and ABC plans were compared in terms of target coverage and dose to other 
organs at risk. The FB plans had a higher PTV90 (p = 0.01) and PTV95 (p < 
0.001). There was no significant difference in spinal cord maximum dose (p = 
0.5) (Table 5). 
  
Discussion 
In this study we assessed the feasibility and reproducibility, particularly of tumour 
position, of using ABC during a radical course of radiotherapy. 17 out of 18 
patients (94 %) tolerated ABC throughout the full course of treatment with no 
patients finding the device very uncomfortable (unpublished data).The variation 
of intrafraction tumour position was less than the interfraction displacement, 
where 5 /18 patients displayed COM movements of >1cm. The mean (SD) 
variation in the position of GTV centre of the tumour in the 3 consecutive 
planning ABC breath-hold CT scans in 12 patients was 2.0 mm (1.7) in the SI 
direction and marginally less in the AP and LR directions. Mean (SD) 
displacements were greater than those reported by Koshani et al (0.2 (0.7), 0.3 
(1.4) and 0.0 (1.5) mm in the RL, SI and AP directions), although the reported 
maximum displacements were 1.7, 3.1 and 4.2 mm in the respective directions 
[26].  
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Interfraction reproducibility of tumour position showed greater variation than 
intrafraction change. The absolute mean (SD) displacement of tumour centre at 
the end of treatment was 4.5 (5.2), 3.5 (2.9) and 3.4 (3.8) mm in the SI, RL and 
AP directions. The maximum displacements were 25, 9.7 and 11.7 mm (SI, RL 
and AP respectively) occurring in three different patients. The mean 
displacements are larger than reported displacements of -0.5 (3.8), 0.3 (1.6) and 
-1.3 (3.1) mm in the respective directions, with maximum displacements of 9.0, 
3.8 and 6.8 mm [26]. The mean was calculated using the absolute values of the 
displacements to illustrate the maximum displacement. Maximum displacement 
occurred in the SI direction, followed by the AP and RL directions. 
 
The 25 mm tumour shift recorded for patient 1 was apparently due to resolution 
of underlying lung collapse and consolidation through the treatment course. The 
displacements measured in other patients are not easily explained by observable 
structural lung changes. It is likely that breathing patterns change over time, so 
that the residual volume from which the ABC breath-hold starts, and therefore the 
actual breath-hold total lung volume, varies. A change in the size and shape of 
the lungs and physiological changes in lung tissue during a course of 
radiotherapy, which are difficult to assess by conventional imaging may also 
contribute to the observed alteration in tumour position. There is a suggestion 
from our results that greater reduction in GTV volume over the treatment course 
(i.e. response to treatment) is associated with greater position variation. A study 
assessing change in GTV size during RT using 4DCT or breath-hold CT scans 
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found median reduction in GTV size of 25 % after approximately 30 Gy and 44 % 
after 50 Gy (p = < 0.001) but did not report significant shift of tumour outside the 
treated volume [27]. 
 
In looking further at possible reasons for tumour position variation we 
retrospectively assessed both breath-hold lung volume consistency and the 
relationship between diaphragm and tumour position for some of the cohort 
treated with ABC. As expected the lung volumes for the 3 consecutive ABC 
baseline scans were consistent (mean difference 2.5 %), whereas there was 
greater discrepancy when comparing lung volumes over the treatment course 
(mean difference 7 % for ABCmid and 4.6 % for ABCend when compared with 
ABC1). However, GTV centre position variation and diaphragm position change 
were not significantly correlated. These results suggest that tumour position 
variation cannot be explained fully by varying breath-hold lung volume, and that 
the diaphragm should not be used as a surrogate for tumour position when using 
electronic portal imaging for treatment verification. 
 
The study methodology, particularly intraobserver variation in contouring, may 
also contribute to the observed displacements [28] and this may be confounded 
by the absence of intravenous contrast in ABC scans hampering tumour outlining 
in or near the mediastinum. The use of rigid manual image registration in the first 
part of the study could also have introduced a small inaccuracy. 
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The calculated CTV-PTV margins using ABC and taking into account all errors 
were 17.5 mm in the SI direction, 11.5 mm in the RL direction and 11.4 mm AP. 
These are larger in all directions than our standard margins of 15 mm, 10 mm 
and 10mm in respective directions, due in part to patient set-up errors. While it is 
not possible to remove all systematic error from radiotherapy treatment, a 
potentially large benefit would be seen with better immobilization. When a 
theoretically reduced set-up error with a standard deviation of 1.5 mm was 
applied to a margin calculation using ABC, margins could be reduced to 7.6 mm 
SI, 5.4 mm AP and 4.7 mm RL from 10.2 mm SI, 10.7 mm AP and 8.8 mm RL, 
leading the authors to conclude that in the majority of cases better immobilization 
and tumour targeting were likely to have a greater impact on margin size than 
motion management [29]. Our results also suggest that standard margins may 
not be adequate in some patients.   
 
The calculated margins in our previous work in a different patient cohort scanned 
but not treated with ABC during RT were 12 mm SI, 9.0 mm AP and 8.3 mm RL 
[24]. These margins were not applied in the current study because the 
reproducibility of ABC had not been determined throughout a course of 
radiotherapy.  We have since recalculated margins based on this study and the 
previous data and clinically implemented ABC using margins of 1cm with an 
image guided and adaptive therapy protocol. However the clinical effects of the 
dosimetric consequences of margin reduction are not known. The slower dose 
build-up through lung tissue means it is often not possible to cover the PTV with 
  Brock 17 
the 95% isodose. This is accepted as unavoidable, particularly as the margins 
used ensure that the 95% isodose adequately covers the GTV. If the margins are 
reduced due to improvements in tumour immobility, it must be ensured that this 
does not impinge on GTV coverage, potentially negating any benefits from dose 
escalation. 
 
 Mean reductions in V20, V13 and MLD of 13 %, 12 % and 13 % (all p ≤ 0.001) 
respectively were achieved for ABC compared with free-breathing plans, despite 
no alteration in PTV margin to take reduced tumour motion into account. The 
benefit is likely to be due to the significant increase in total lung volume seen for 
ABC compared with free-breathing CT scans (mean increase 41 %, p < 0.001), 
reducing the relative volume of lung within the high dose volume. The use of 
ABC in radical RT of NSCLC should reduce the risk of severe lung toxicity 
without changing any other aspect of the treatment. Alternatively, dose may be 
escalated with ABC whilst maintaining the same risk of lung toxicity. These 
results have been used to model the potential increase in tumour control if ABC 
were used in conjunction with escalated dose [30] and to develop a clinical 
protocol to treat NSCLC using ABC with dose escalation. 
 
The variation in the position of the tumour was assessed by CT scan over a 
course of treatment. The use of the CT scanner away from the treatment 
situation is a potential source of error. Since the introduction of cone beam CT, 
imaging has been carried out on the treatment couch in free-breathing, allowing 
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for regular adaptive adjustments. As the use of ABC has become part of 
standard practice, ideally image guidance in breath-hold should be performed 
prior to each treatment.  
 
Conclusion 
The ABC device can be used throughout radical radiotherapy for NSCLC with 
reproducible intrafraction tumour position. However, because of tumour position 
shift over time (interfraction variation), and patient set-up errors, a reduction in 
the size of the PTV margin is nevertheless not possible without image guidance 
and/or improved set-up. 
Even with standard margins ABC leads to reduction in V20, V13 and MLD, most 
likely due to increased total lung volume and this allows for significant equitoxic 
dose escalation.  
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Figure Legend 
Figure 1. Example of a patient with significant volume and tumour position 
changes over the course of radiotherapy. Intrafraction tumour position at 
planning was consistent (left), but significant shrinkage and shift occurred from 
baseline to the end of radiotherapy (right). PTV, planning target volume; GTV, 
gross tumour volume; RT, radiotherapy. 
 
 
 
